CPE Capital has successfully exited its investment in Cell Care by selling the company to Generate Life Sciences, leveraging significant growth and strategic initiatives during their ownership.
Information on the Target
Cell Care has established itself as a notable player in the newborn stem cell banking industry, providing valuable services to parents seeking to preserve their children's stem cells for future medical use. Over the course of CPE Capital's 2.5-year investment, Cell Care not only maintained its operational resilience but also achieved notable growth in EBITDA, even amidst the challenges posed by the COVID-19 pandemic.
During this period, several strategic initiatives were implemented that contributed to enhanced performance and value creation. These included forging new partnerships with hospitals in Australia, optimizing marketing strategies, revising the pricing structure in Canada, and exploring additional opportunities for expansion.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Australia's Market
The newborn stem cell banking sector in Australia has seen a growing demand as parents become increasingly aware of the potential medical benefits of stem cell preserva
Similar Deals
Generate Life Sciences
invested in
Cell Care
in
in a Other Private Equity deal